-

Dexcom Canada and RxFood Corporation Partner on Industry-Leading, AI-powered Nutrition and Glucose Monitoring Solution for Diabetes Management and Personalized Therapeutic Nutrition

The partnership will pair cutting-edge technology from Dexcom with daily food tracking to provide a more comprehensive and personalized care experience for those living with diabetes

BURNABY, British Columbia--(BUSINESS WIRE)--Dexcom, Inc. (NASDAQ: DXCM), a global leader in real-time continuous glucose monitoring (rtCGM) for people with diabetes, and RxFood Corporation, the leader in AI-driven personalized nutrition assessments, announced today a first-of-its-kind partnership in Canada to introduce an improved digital health solution for those living with diabetes.

The next generation RxFood app, featuring Dexcom CGM glucose data integration, is now available to health care program stakeholders across Canada including clinics, hospitals, health authorities, pharmacies, insurers, and employers, to incorporate into diabetes and nutrition management programming. Through these programs, Canadians using the Dexcom G6 CGM system or the Dexcom G7 CGM system, once commercially available, will have access to the combined power of food data and glucose data, to obtain a more comprehensive personalized understanding of their health and glucose control.

"At Dexcom, introducing industry-leading technology that transforms day-to-day diabetes management for users around the world has been our primary goal for over two decades," said André Côté, Vice President and General Manager, Dexcom Canada. “Working closely with RxFood on this innovative solution has allowed us to advance this even further. We look forward to demonstrating how our partnership will help continue to simplify diabetes management for individuals and families, providing deep, actionable nutritional insights to enhance overall health."

Within the RxFood app, Dexcom CGM users can capture photos of their meals, eliminating the need for manual food and nutrition tracking. As they photo-log their food, RxFood will continuously generate detailed diet quality metrics that are combined with glucose data, making it easily accessible to both patients and their dedicated clinicians. The combination of RxFood with Dexcom CGM addresses the need for unified, time-matched food and glucose data reports to effectively manage diabetes and enable personalized nutritional guidance at scale.

The efficacy of RxFood was demonstrated through a rigorous three-year clinical trial at The Hospital for Sick Children in Toronto, Ontario. This trial focused on families of children with diabetes and yielded impressive results, including improved accuracy in carbohydrate counting; a notable decrease in counting errors exceeding 10g; and lower A1C levels1. Additionally, as the RxFood technology has been adopted and deployed within clinical settings across Canada, it was found to help reduce the time associated with day-to-day diabetes management for parents, while allowing clinicians to have more complete food records, supporting the development of more personalized care recommendations for families.

“Continuous glucose monitoring is a key component of diabetes management, but food type, amount, and timing are also important variables. By seamlessly integrating food data with insulin dosing, exercise, and glucose information, a comprehensive understanding of how specific food items impact glucose levels is made possible,” said Dr. Jeffrey Alfonsi, MD, Internist & Obesity Medicine Physician and Chief Medical Officer at RxFood Corporation. “These invaluable insights empower both patients and clinicians to enhance diabetes management by identifying and addressing factors that contribute to glucose excursions, leading to improved overall control and care.”

For more information on how RxFood and Dexcom are promoting individual well-being through improved nutrition and diabetes management, and for updates on program availability, please visit www.rxfood.co/dexcom.

About Dexcom, Inc.

Dexcom, Inc. empowers people to take control of diabetes through innovative continuous glucose monitoring (CGM) systems. Headquartered in San Diego, California in the United States, and with operations in Canada, Dexcom has emerged as a leader in diabetes care technology. By listening to the needs of users, caregivers, and providers, Dexcom simplifies and improves diabetes management around the world. For more information about Dexcom CGM, visit www.dexcom.com.

About RxFood Corporation

RxFood is becoming the gold standard for medical nutrition therapy by using powerful AI models. Developed through a community of healthcare professionals and patients, RxFood transforms photos of what individuals eat into powerful dietary assessments and recommendations that is used by Clinicians to augment patient care, and by patients to support the continuity of their care. RxFood provides increased efficiency for clinicians, raising the bar for patient engagement and satisfaction in nutrition therapy, and improved health outcomes. Outcomes to date have gained the attention from the insurer and corporate environments, bringing to life personalized nutrition and food as medicine. For more information about RxFood, visit www.rxfood.co.

1 Alfonsi JE, et al. Carbohydrate Counting App Using Image Recognition for Youth With Type 1 Diabetes: Pilot Randomized Control Trial. JMIR Mhealth Uhealth. 2020;8(10):e22074.

Contacts

For further information, please contact:
Laura Andrejicka at Andrejicka@veritasinc.com
RxFood at media@rxfood.co

Dexcom, Inc.

NASDAQ:DXCM

Release Versions

Contacts

For further information, please contact:
Laura Andrejicka at Andrejicka@veritasinc.com
RxFood at media@rxfood.co

More News From Dexcom, Inc.

Dexcom Further Advances Vision of Glucose Biosensing for All

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, today announced at Aspen Ideas: Health a series of milestones that advance its vision of making glucose biosensing more accessible. Notably, the company announced pediatric clearance for the Stelo Glucose Biosensor and the launch of its fully reimagined Stelo app experience in July for Apple iPhone and Android users in the United States.“Glucose matters for everyone and better understanding it can h...

Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) announced today results from the CONNECT randomized controlled trial, demonstrating the use of Dexcom G7 leads to clinically and statistically significant reduction in A1C and improvement in glucose control among people with Type 2 diabetes not using insulin compared with a routine care control group using self-monitoring of blood glucose.1 Researchers presented these results today as an oral presentation at the 2026 Scientific Sessions of...

Dexcom Reaffirms CGM Benefits for All People With Diabetes and Continues Momentum Toward Earlier Stage Intervention and Preventative Care at ADA 2026

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) will present new clinical findings, product advancements and strategic business initiatives reinforcing its commitment to improving care for people with all types of diabetes and ushering in a new era of early stage CGM intervention and preventative care at the American Diabetes Association’s Scientific Sessions in New Orleans, June 5-8, 2026. “Dexcom has built a legacy of innovation within the diabetes space and as we look to the future, e...
Back to Newsroom